Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from EXACT Therapeutics AS ( (DE:56F) ).
EXACT Therapeutics announced that its Phase 2 ENACT trial for treating locally advanced pancreatic cancer will be presented at the 2025 AACR Special Conference. The trial, conducted in collaboration with HonorHealth Research Institute, investigates the efficacy and safety of acoustic cluster therapy combined with modified FOLFIRINOX. This presentation could enhance the company’s visibility and influence in the oncology sector, potentially impacting its market position and stakeholder interests.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that specializes in using ultrasound and microbubbles for targeted drug delivery in oncology. Their Acoustic Cluster Therapy (ACT®) is a unique approach that can be applied to various therapeutic agents in oncology and other medical fields, including brain diseases. The company’s shares are traded on Euronext Growth Oslo.
Average Trading Volume: 29,368
Current Market Cap: NOK141.7M
For a thorough assessment of 56F stock, go to TipRanks’ Stock Analysis page.